Search research articles
Contact Us
Filters
Showing results (971-980 of 1,482) with videos related to
Page
of 149
Sort By:
Cancer
|
March 4, 2020
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
Betül Oran, Guillermo Garcia-Manero, Rima M Saliba, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 25, 2015
Cold season emissions dominate the Arctic tundra methane budget
Donatella Zona, Beniamino Gioli, Róisín Commane, et al.
The Lancet. Haematology
|
August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
Tapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Haematologica
|
May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Kelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Leukemia & Lymphoma
|
July 19, 2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Page
of 149
Search research articles
Search
Showing results (971-980 of 1,482) with videos related to
Sort By:
Page
of 149
Cancer
|
March 4, 2020
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
Betül Oran, Guillermo Garcia-Manero, Rima M Saliba, et al.
Blood Advances
|
April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Curtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 25, 2015
Cold season emissions dominate the Arctic tundra methane budget
Donatella Zona, Beniamino Gioli, Róisín Commane, et al.
The Lancet. Haematology
|
August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
Tapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
Haematologica
|
May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Blood Cancer Journal
|
May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
Musa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology
|
April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib
Kelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Leukemia & Lymphoma
|
July 19, 2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Page
of 149